The Power and Promise of RNA – Duke University School of Medicine

The word messenger RNA, or mRNA for short, went from scientific jargon to everyday conversation during the pandemic because of the molecule's starring role in COVID-19 vaccines.

Messenger RNA contains blueprints for proteins that do all sorts of jobs in our bodies. In COVID-19 vaccines, it contains instructions to make proteins similar to the spikes on the coronavirus. This encourages the immune system to create antibodies to fight the virus if we encounter it in the future.

Vaccines are just the beginning of the therapeutic potential of RNA. Scientists at Duke University School of Medicine have long probed the mysteries of RNA, with an eye on harnessing its power for new and better therapies for cancer, diabetes, heart disease and more.

RNA translates our genetic code into action, using information in our genes to create a functioning organism. But the body has ways to modify RNA to change gene expression. These RNA modifications, crucial for normal development, sometimes go awry in disease states.

At Duke, several scientists study RNA modifications. Thats an area of strength for us, said cardiologist Christopher Holley, MD, PhD, associate professor of medicine and assistant research professor in Department of Molecular Genetics and Microbiology. We cant think of any other university in the world that has as large a group studying RNA modifications as there is here at Duke.

Unlike mRNA, not all RNA contains blueprints for proteins. Some types of RNA guide the modification of mRNA, essentially turning genes on or off without changing the genetic code itself.

In RNA, the genetic code is written in base chemicals referred to by the letters A, G, C, and U. Holley compares RNA modifications to an asterisk. These modifications dont change the letter sequence of RNA, he said. You still have the same word, but there is some extra information.

Holley studies a type of modification-guiding RNA called small nucleolar RNA, or snoRNA. While snoRNAs have a role in normal biology, they are also active in some unhealthy processes, including oxidative stress, which damages cells.

Holley has found that turning snoRNAs off in mice protects the mice from diabetes, atherosclerosis, and the symptoms of sickle cell disease, with no apparent side effects. There seems to be a beneficial effect of dialing down these snoRNAs, he said, because we think they really promote oxidative stress damage.

Holley, whose doctorate is in pharmacology, is designing a molecule that will attach itself to snoRNAs, causing them to self-destruct. With the help of Dukes Office of Technology and Commercialization, Holley and a colleague, launched a company called snoPanther to help bring the idea to market.

The dream is that we would be able to turn these into drugs for people, he said.

Hes especially interested in developing better treatments to help his patients avoid heart attacks. Hes actively pursuing snoRNA treatments for diabetes and sickle cell disease as well.

There are hundreds of snoRNAs, he said, and we think in general it could be a whole new class of molecules we could target for drug development.

One of the reasons Kate Meyer, PhD, assistant professor in biochemistry, came to Duke was the concentration of RNA researchers here. That was a big draw for me, Meyer said. Its great because we all study similar concepts but were different enough that we dont compete with each other; we complement each other.

Meyer studies a modification called m6A, in which a molecule called a methyl group gets added to a particular site on RNA. Proper regulation of m6A is required for cells and organisms to function and for animals to develop normally, she said. Dysregulation of m6A has been linked to a variety of different diseases, most notably several cancers.

When she was a postdoctoral researcher, Meyer helped develop the first technique to map m6A sites in cells. At Duke, she and her lab members have developed new methods which can detect m6A from very low amounts of RNA, allowing researchers to zoom in and identify sites in a single cell.

Single-cell m6A profiling has provided new insights into m6A biology, she said. The new technique revealed about 170,000 m6A sites throughout the body many more than scientists had imagined.

Meyer, who is particularly interested in neuroscience applications, studies the functions of m6A in the brain, where m6A is known to be active in response to axonal injury, neural diseases, and brain cancer.

The more we understand about methylation and how it is regulated in cells, she said, the better positioned we are to develop novel therapeutics.

Meyer recently served on the National Academies of Sciences, Engineering and Medicine committee that compiled a report providing a roadmap for achieving the complete sequencing of RNA molecules and their modifications from one end to the other. Meyer believes this feat will help enable researchers, clinicians, and the biotechnology sector to more fully harness the power of RNA.

Before Meyer joined the Duke faculty, Stacy Horner, PhD, associate professor in integrative immunobiology, came across Meyers postdoctoral paper mapping m6A sites. Horner decided to use the technique in her own lab, in a slightly different application.

Horner studies RNA in viruses and she wanted to look for m6A in viral RNA. I felt like we should look at this because no one was exploring this, she said, and then, with her work, we were able to do this.

She found that viral RNA, like our RNA, does contain m6A sites, a finding that is informing further research. We have been looking at how proteins in the body might sense a specific pattern in viral RNA that contains these modifications, she said.

Her overall goal is to understand how our bodies distinguish viral RNA (which the immune system should attack) from our own RNA (which the immune system should ignore).

In illuminating these biological mechanisms, Horners research could lead to treatments for autoimmune diseases in which the body's immune system attack its own RNA. You need to know the biochemical mechanisms that distinguish viral RNA from our own RNA so you know what to target, she said.

Her work will also be important in understanding how to design RNA therapeutics so that the body doesnt identify them as something to attack.

Horner, who also has appointments in the departments of cell biology, medicine, molecular genetics and microbiology, and the Duke Cancer Institute, now works alongside Meyer to co-direct the Center for RNA Biology, the intellectual home for RNA research at Duke.

We share what were learning and we share technology, she said. It really helps us push the envelope.

As a relative newcomer to RNA research, Josh Huang, PhD, the Duke School of Medicine Distinguished Professor of Neuroscience, appreciates the rich environment of Dukes in-house expertise, which has helped him get up to speed on RNA after years of studying neural circuitry.

Hes interested in using RNA as a tool to learn more about cell types and to manipulate cells to treat disease.

He has recently developed a technique he calls CellREADR to program engineered mRNA to bind to RNA in particular cells in the body and deliver instructions.

Imagine the target sequence is in RNA in a cancer cell. Once the engineered mRNA is attached to the cancer RNA, it issues instructions. Its a message that we want to deliver to the cancer cell, Huang said, to tell the cancer cell to die or to label the cancer cell so that immune cells will kill it.

READ MORE New RNA-based tool can illuminate brain circuits, edit specific cells

The technology has applications far beyond cancer. In Parkinsons disease patients, for example, engineered mRNA could locate cells involved in synthesizing dopamine, attach to the RNA in those cells, and deliver instructions to fix the malfunction.

Like Holley, Huang has started a company to bring his technology to market, called Doppler Bio, with help from Dukes Office of Technology and Commercialization.

RNA therapies are quicker and less expensive to manufacture than more traditional pharmaceuticals, which is one of the reasons the COVID-19 vaccines were designed and produced so quickly. They also have the potential to be easily tailored for different vaccines and disease treatments.

One of the most exciting benefits for patients is the possibility of increased effectiveness with fewer side effects.

In the case of cancer, say, RNA therapy could potentially destroy cancer cells without affecting other cells. This contrasts with currently available radiation and chemotherapy, which damage a broad swath of normal cells in the body.

Broadly speaking, that is the promise of RNA therapeutics precision and effectiveness, Huang said.

Mary-Russell Roberson is a freelance writer in Durham.

Eamon Queeney is assistant director of multimedia and creative at the Duke School of Medicine.

Continued here:
The Power and Promise of RNA - Duke University School of Medicine

New surfactant could improve lung treatments for premature babies – ASBMB Today

Scientists have developed a new lung surfactant that is produced synthetically rather than relying on the use of animal tissues. With further development, the formulation could provide a cheaper and more readily available alternative to Infasurf, a medication used to prevent and treat respiratory distress in premature babies.

Surfactants are substances that decrease surface tension where liquids interface with other liquids, gases or solids. In addition to their use in medicines, they are found in a wide range of products including detergents, cosmetics, motor oils and adhesives.

Scientists at Discover BMB in San Antonio reported a new lung surfactant that is produced synthetically rather than derived using animal tissues. It might eventually provide a cheaper and more accessible alternative to medication currently used to prevent and treat respiratory distress in premature babies.

Suzanne Farver Lukjan, a lecturer in chemistry at Troy University in Alabama, led the work.

A synthetic surfactant could potentially have a longer shelf life, lower production costs, have less batch variability and pose less risk of an immune response compared to animal-derived lung surfactants, she said. We hope our formulation will one day be used in hospitals.

Lukjan will present the research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, which is being held March 2326 in San Antonio.

Lung surfactants help premature babies breathe while their lung cells finish developing. In addition to offering a potential alternative to replace Infasurf for babies, researchers say the new synthetic surfactant could be useful for treating adults with lung injuries as a result of diseases such as chronic obstructive pulmonary disorder, miners lung or emphysema.

Researchers have previously attempted to develop synthetic lung surfactants, but some have been removed from the market and others have not been able to lower surface tension as well as animal-derived formulations.

In the new work, Lukjans team created candidate surfactants from synthetic lipids (fats) and peptides (short chains of amino acids) and then tested their surface-tension-lowering capabilities. They aimed to mimic the composition, lipid phase behavior and biophysical function of Infasurf as closely as possible.

After tweaking a step in the sample preparation process, the researchers found a few formulations that showed particular promise. Although tests demonstrated that the chemical behavior of the synthetic surfactants was quite different from that of Infasurf, the new surfactants were able to mimic the drugs functionality in terms of lowering surface tension and seem to achieve the optimal range in terms of peptide concentration.

As a next step, Lukjan said, the group plans to continue to refine and test their formulation to further optimize the combination of lipids and peptides. The surfactant would also need to undergo safety testing before it could be used clinically.

This work was partially funded by ONY Biotech Inc., maker of Infasurf.

Suzanne Lukjan will present this research from 4:30 to 6:30 p.m. CDT on Monday, March 25, in the exhibit hall of the Henry B. Gonzlez Convention Center (Poster Board No. 210) (abstract).

Read more here:
New surfactant could improve lung treatments for premature babies - ASBMB Today

Complex Organic Chemistry In Sulfuric Acid And Life On Venus – Hackaday

Finding extraterrestrial life in any form would be truly one of the largest discoveries in humankinds history, yet after decades of scouring the surface of Mars and investigating other bodies like asteroids, we still have found no evidence. While we generally assume that were looking for carbon-based lifeforms in a water-rich environment like Jupiters moon Europa, what if complex organic chemistry would be just as happy with sulfuric acid (H2SO4) as solvent rather than dihydrogen monoxide (H2O)? This is the premise behind a range of recent studies, with a newly published research article in Astrobiology by [Maxwell D. Seager] and colleagues lending credence to this idea.

Previous studies have shown that organic chemistry in concentrated sulfuric acid is possible, and that nucleic acid bases including adenosine, cytosine, guanine, thymine and uracil which form DNA are also stable in this environment, which is similar to that of the Venusian clouds at an altitude where air pressure is roughly one atmosphere. In this new article, twenty amino acids were exposed to the concentrations of sulfuric acid usually found on Venus, at 98% and 81%, with the rest being water. Of these, 11 were unchanged after 4 weeks, 9 were reactive on their side chains, much like they would have been in pure water. Only tryptophan ended up being unstable, but as the researchers note, not all amino acids are stable in water either.

The limitations of this research is of course that it was performed in a laboratory environment, with uncontaminated concentrated sulfuric acid, rather than the Venusian clouds with their trace elements of other gases such as CO2 and the constant bombardment with meteors that have been shown to often be laced with such amino acids. Future research will take these variables into account, even as scientists cannot wait to get data from upcoming Venus missions, with better sensors that may just catch a glimpse of such organic chemistry in action.

Read more from the original source:

Complex Organic Chemistry In Sulfuric Acid And Life On Venus - Hackaday

International Brain Research Organisation (IBRO) Diversity Grants 2024 Opportunity Desk – Opportunity Desk

Deadline: April 15, 2024

Applications are open for the International Brain Research Organisation (IBRO) Diversity Grants 2024. IBROs core values aim to serve the global neuroscience community through the promotion of diversity, equity, and inclusion in neuroscience research. In alignment with this vision, the IBRO Diversity Grants seek to support events that prioritize and foster regional and gender diversity in neuroscience. This program specifically targets neuroscience societies and other event organizers.

Applicants interested in applying to this funding program are encouraged to address the unique needs prevalent in their region and/or country. IBRO acknowledges the fact that cultural, socio-economic and infrastructural contexts shape the practice of neuroscience globally and encourages applicants to craft proposals tailored to address these unique diversity challenges.

Funds will be transferred according to an 80:20 format. This means that 80% of the grant will be awarded two months prior to the start date of the event, whereas the remaining 20% will be processed upon completion of the event and submission of the required grant report.

Grant

Eligibility

Application

Click here to apply

For more information, visit IBRO Diversity Grants.

Visit link:
International Brain Research Organisation (IBRO) Diversity Grants 2024 Opportunity Desk - Opportunity Desk

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share – Defense World

Vigil Neuroscience, Inc. (NASDAQ:VIGL Free Report) Research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Vigil Neuroscience in a research report issued on Wednesday, March 27th. HC Wainwright analyst A. Fein expects that the company will earn ($0.58) per share for the quarter. HC Wainwright has a Buy rating and a $24.00 price objective on the stock. The consensus estimate for Vigil Neurosciences current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vigil Neurosciences Q3 2024 earnings at ($0.58) EPS.

Separately, Morgan Stanley cut Vigil Neuroscience from an equal weight rating to an underweight rating and decreased their price objective for the company from $13.00 to $4.00 in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $17.40.

NASDAQ:VIGL opened at $3.41 on Thursday. The stocks fifty day moving average price is $3.06 and its two-hundred day moving average price is $4.32. Vigil Neuroscience has a 52-week low of $2.53 and a 52-week high of $11.11. The company has a market cap of $122.35 million, a price-to-earnings ratio of -1.60 and a beta of 1.80.

Several hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Vigil Neuroscience during the fourth quarter worth approximately $27,000. Royal Bank of Canada acquired a new stake in Vigil Neuroscience during the second quarter worth approximately $33,000. California State Teachers Retirement System acquired a new stake in Vigil Neuroscience during the second quarter worth approximately $50,000. Wells Fargo & Company MN lifted its position in Vigil Neuroscience by 6,988.4% during the second quarter. Wells Fargo & Company MN now owns 6,096 shares of the companys stock worth $57,000 after acquiring an additional 6,010 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Vigil Neuroscience during the second quarter worth approximately $86,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

(Get Free Report)

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share - Defense World

Household Chemicals Linked to Brain Health Risks – Neuroscience News

Summary: Certain household chemicals, including those found in personal-care products and furniture, pose a risk to brain health, potentially contributing to multiple sclerosis and autism. The study reveals that these chemicals damage oligodendrocytes, essential cells for nerve cell protection.

Key findings include the identification of harmful organophosphate flame retardants and quaternary ammonium compounds, with the latter increasing in use since the COVID-19 pandemic. This groundbreaking research suggests a need for further investigation into the impact of these chemicals on neurological diseases and calls for more rigorous scrutiny and regulation to protect public health.

Key Facts:

Source: Case Western Reserve

A team of researchers from theCase Western Reserve University School of Medicinehas provided fresh insight into the dangers some common household chemicals pose to brain health.

They suggest that chemicals found in a wide range of items, from furniture to hair products, may be linked to multiple sclerosis and autism spectrum disorders.

Neurological problems impact millions of people, but only a fraction of cases can be attributed to genetics alone, indicating that unknown environmental factors are important contributors to neurological disease.

The new study published today in the journalNature Neuroscience, discovered that some common home chemicals specifically affect the brains oligodendrocytes, a specialized cell type that generates the protective insulation around nerve cells.

Loss of oligodendrocytes underlies multiple sclerosis and other neurological diseases,said the studys principal investigator,Paul Tesar,the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics and director of the Institute for Glial Sciences at the School of Medicine.

We now show that specific chemicals in consumer products can directly harm oligodendrocytes, representing a previously unrecognized risk factor for neurological disease.

On the premise that not enough thorough research has been done on the impact of chemicals on brain health, the researchers analyzed over 1,800 chemicals that may be exposed to humans.

They identified chemicals that selectively damaged oligodendrocytes belong to two classes: organophosphate flame retardants and quaternary ammonium compounds.

Since quaternary ammonium compounds are present in many personal-care products and disinfectants, which are being used more frequently since the COVID-19 pandemic began, humans are regularly exposed to these chemicals. And many electronics and furniture include organophosphate flame retardants.

The researchers used cellular and organoid systems in the laboratory to show that quaternary ammonium compounds cause oligodendrocytes to die, while organophosphate flame retardants prevented the maturation of oligodendrocytes.

They demonstrated how the same chemicals damage oligodendrocytes in the developing brains of mice. The researchers also linked exposure to one of the chemicals to poor neurological outcomes in children nationally.

We found that oligodendrocytesbut not other brain cellsare surprisingly vulnerable to quaternary ammonium compounds and organophosphate flame retardants, saidErin Cohn, lead author and graduate student in the School of MedicinesMedical Scientist Training Program.

Understanding human exposure to these chemicals may help explain a missing link in how some neurological diseases arise.

The association between human exposure to these chemicals and effects on brain health requires further investigation, the experts warned. Future research must track the chemical levels in the brains of adults and children to determine the amount and length of exposure needed to cause or worsen disease.

Our findings suggest that more comprehensive scrutiny of the impacts of these common household chemicals on brain health is necessary, Tesar said.

We hope our work will contribute to informed decisions regarding regulatory measures or behavioral interventions to minimize chemical exposure and protect human health.

Additional contributing researchers from Case Western Reserve School of Medicine and from theU.S. Environmental Protection Agencyincluded Benjamin Clayton, Mayur Madhavan, Kristin Lee, Sara Yacoub, Yuriy Fedorov, Marissa Scavuzzo, Katie Paul Friedman and Timothy Shafer.

The research was supported by grants from theNational Institutes of Health,National Multiple Sclerosis Society,Howard Hughes Medical InstituteandNew York Stem Cell Foundation, and philanthropic support by sTF5 Care and the Long, Walter, Peterson, Goodman and Geller families.

Author: William Lubinger Source: Case Western Reserve Contact: William Lubinger Case Western Reserve Image: The image is credited to Neuroscience News

Original Research: The findings will appear in Nature Neuroscience

See the original post:
Household Chemicals Linked to Brain Health Risks - Neuroscience News

Hereditary Alzheimer’s Transmitted Via Bone Marrow Transplants – Neuroscience News

Summary: Alzheimers disease, traditionally seen as a brain-centric condition, may have systemic origins and can be accelerated through bone marrow transplants from donors with familial Alzheimers to healthy mice.

A new study underscores the diseases potential transmission via cellular therapies and suggests screening donors for Alzheimers markers to prevent inadvertent disease transfer.

By demonstrating that amyloid proteins from peripheral sources can induce Alzheimers in the central nervous system, this research shifts the understanding of Alzheimers towards a more systemic perspective, highlighting the need for cautious screening in transplants and blood transfusions.

Key Facts:

Source: Cell Press

Familial Alzheimers disease can be transferred via bone marrow transplant, researchers show March 28 in the journalStem Cell Reports. When the team transplanted bone marrow stem cells from mice carrying a hereditary version of Alzheimers disease into normal lab mice, the recipients developed Alzheimers diseaseand at an accelerated rate.

The study highlights the role of amyloid that originates outside of the brain in the development of Alzheimers disease, which changes the paradigm of Alzheimers from being a disease that is exclusively produced in the brain to a more systemic disease.

Based on their findings, the researchers say that donors of blood, tissue, organ, and stem cells should be screened for Alzheimers disease to prevent its inadvertent transfer during blood product transfusions and cellular therapies.

This supports the idea that Alzheimers is a systemic disease where amyloids that are expressed outside of the brain contribute to central nervous system pathology, says senior author and immunologist Wilfred Jefferies, of the University of British Columbia.

As we continue to explore this mechanism, Alzheimers disease may be the tip of the iceberg and we need to have far better controls and screening of the donors used in blood, organ and tissue transplants as well as in the transfers of human derived stem cells or blood products.

To test whether a peripheral source of amyloid could contribute to the development of Alzheimers in the brain, the researchers transplanted bone marrow containing stem cells from mice carrying a familial version of the diseasea variant of the human amyloid precursor protein (APP) gene, which, when cleaved, misfolded and aggregated, forms the amyloid plaques that are a hallmark of Alzheimers disease.

They performed transplants into two different strains of recipient mice: APP-knockout mice that lacked an APP gene altogether, and mice that carried a normal APP gene.

In this model of heritable Alzheimers disease, mice usually begin developing plaques at 9 to 10 months of age, and behavioral signs of cognitive decline begin to appear at 11 to 12 months of age. Surprisingly, the transplant recipients began showing symptoms of cognitive decline much earlierat 6 months post-transplant for the APP-knockout mice and at 9 months for the normal mice.

The fact that we could see significant behavioral differences and cognitive decline in the APP-knockouts at 6 months was surprising but also intriguing because it just showed the appearance of the disease that was being accelerated after being transferred, says first author Chaahat Singh of the University of British Columbia.

In mice, signs of cognitive decline present as an absence of normal fear and a loss of short and long-term memory. Both groups of recipient mice also showed clear molecular and cellular hallmarks of Alzheimers disease, including leaky blood-brain barriers and buildup of amyloid in the brain.

Observing the transfer of disease in APP-knockout mice that lacked an APP gene altogether, the team concluded that the mutated gene in the donor cells can cause the disease and observing that recipient animals that carried a normal APP gene are susceptible to the disease suggests that the disease can be transferred to health individuals.

Because the transplanted stem cells were hematopoietic cells, meaning that they could develop into blood and immune cells but not neurons, the researchers demonstration of amyloid in the brains of APP knockout mice shows definitively that Alzheimers disease can result from amyloid that is produced outside of the central nervous system.

Finally the source of the disease in mice is a human APP gene demonstrating the mutated human gene can transfer the disease in a different species.

In future studies, the researchers plan to test whether transplanting tissues from normal mice to mice with familial Alzheimers could mitigate the disease and to test whether the disease is also transferable via other types of transplants or transfusions and to expand the investigation of the transfer of disease between species.

In this study, we examined bone marrow and stem cells transplantation. However, next it will be important to examine if inadvertent transmission of disease takes place during the application of other forms of cellular therapies, as well as to directly examine the transfer of disease from contaminated sources, independent from cellular mechanisms, says Jefferies.

Funding:

This research was supported by the Canadian Institutes of Health Research, the W. Garfield Weston Foundation/Weston Brain Institute, the Centre for Blood Research, the University of British Columbia, the Austrian Academy of Science, and the Sullivan Urology Foundation at Vancouver General Hospital.

Author: Kristopher Benke Source: Cell Reports Contact: Kristopher Benke Cell Reports Image: The image is credited to Neuroscience News

Original Research: The findings will appear in Stem Cell Reports

Continued here:
Hereditary Alzheimer's Transmitted Via Bone Marrow Transplants - Neuroscience News

Prolonged Progestogen Use Linked to Brain Tumor Risk – Neuroscience News

Summary: A new study highlights a significant link between prolonged use of certain progestogen hormone drugs and an increased risk of developing intracranial meningioma, a type of brain tumor. Researchers analyzed data from 18,061 women who underwent surgery for intracranial meningioma, comparing their progestogen use to 90,305 controls.

The study found that prolonged use of specific progestogens, including medrogestone, medroxyprogesterone acetate, and promegestone, is associated with an elevated risk of requiring surgery for meningioma. This research underscores the urgent need for further studies to understand this risk fully, especially given the widespread use of these hormones in treating conditions like endometriosis and as part of contraceptive methods.

Key Facts:

Source: BMJ

Prolonged use of certain progestogen hormone drugs is associated with an increased risk of developing a type of brain tumour known as an intracranial meningioma, finds a study from France published byThe BMJtoday.

The researchers say this study is the first to assess the risk associated with progestogens used by millions of women worldwide, and further studies are urgently needed to gain a better understanding of this risk.

Progestogens are similar to the natural hormone progesterone, which are widely used for gynaecological conditions such as endometriosis and polycystic ovary syndrome, and in menopausal hormone therapy and contraceptives.

Meningiomas are mostly non-cancerous tumours in the layers of tissue (meninges) that cover the brain and spinal cord. Factors such as older age, female sex, and exposure to three high-dose progestogens (nomegestrol, chlormadinone, and cyproterone acetate) are already known to increase the risk of meningioma.

But there are many other progestogens for which the risk of meningioma associated with their use has not been estimated individually.

To address this knowledge gap, researchers set out to evaluate the real life risk of intracranial meningioma requiring surgery in women associated with use of several progestogens with different routes of administration.

They used data from the French national health data system (SNDS) for 18,061 women (average age 58) who underwent intracranial meningioma surgery from 2009-18.

Each case was matched to five control women without intracranial meningioma (total 90,305) by year of birth and area of residence.

The progestogens examined were progesterone, hydroxyprogesterone, dydrogesterone, medrogestone, medroxyprogesterone acetate, promegestone, dienogest, and levonorgestrel intrauterine systems.

For each progestogen, use was defined as at least one prescription in the year before hospital admission or within 3-5 years for levonorgestrel intrauterine systems.

Use of at least one of the three high-dose progestogens known to increase the risk of meningioma in the 3 years before hospital admission was also recorded to minimise bias.

After taking account of other potentially influential factors, prolonged use (a year or more) of medrogestone was associated with a 4.1-fold increased risk of intracranial meningioma requiring surgery.

Prolonged use of medroxyprogesterone acetate injection was associated with a 5.6-fold increased risk, and prolonged use of promegestone was linked to a 2.7-fold increased risk.

There appeared to be no such risk for less than one year of use of these progestogens.

As expected, there was also an excess risk of meningioma for women exposed to chlormadinone acetate, nomegestrol acetate, and cyproterone acetate, all of which are known to increase the risk of meningioma.

However, results showed no excess risk of meningioma for progesterone, dydrogesterone, or the widely used hormonal intrauterine systems, regardless of the dose of levonorgestrel they contained.

No conclusions could be drawn about dienogest or hydroxyprogesterone as the number of exposed individuals was too small.

This is an observational study so cant establish cause and effect, and the authors acknowledge that the SNDS database lacked information on all the clinical details and medical indications for which progestogens are prescribed. Nor were they able to account for genetic predisposition and exposure to high dose radiation.

However, they say, given that medroxyprogesterone acetate is estimated to be used for birth control by 74 million women worldwide, the number of attributable meningiomas may be potentially high.

Further studies using other sources of data are urgently needed to gain a better understanding of this risk, they conclude.

Author: BMJ Media Relations Source: BMJ Contact: BMJ Media Relations BMJ Image: The image is credited to Neuroscience News

Original Research: The findings will appear in The BMJ

The rest is here:
Prolonged Progestogen Use Linked to Brain Tumor Risk - Neuroscience News

Anxiety Drives Wishful Thinking to Risky Levels – Neuroscience News

Summary: Individuals tend to become overly optimistic in situations marked by insecurity and anxiety, potentially to their detriment. The research, involving more than 1,700 participants, demonstrated that people are less accurate in recognizing patterns linked to negative outcomes, like electrical shocks or monetary loss, indicating a clear bias towards wishful thinking. Interventions to reduce this bias included simplifying tasks to reduce uncertainty and offering rewards for accuracy, which showed mixed results. The findings suggest that while wishful thinking can help cope with stress, it may also hinder necessary actions in critical situations like health or environmental crises.

Key Facts:

Source: University of Amsterdam

Everyone indulges in wishful thinking now and again. But when is that most likely to happen and when could it actually be harmful?

A new study, led by the University of Amsterdam (UvA), demonstrates unequivocally that the greater the insecurity and anxiety of a situation, the more likely people are to become overly optimistic even to the point where it can prevent us from taking essential action.

The studys results have now been published in the journalAmerican Economic Review.

People arent purely truth-seekers many beliefs are influenced by emotions and driven by what is pleasant or comforting. Like belief in an afterlife or optimism about health outcomes, says Jol van der Weele, professor of Economic Psychology at the UvA. Working alongside professor of Neuroeconomics Jan Engelmann and an international team, Van der Weele set out to answer whether people become overly optimistic when facing potential hardships.

So far studies havent provided clear evidence for wishful thinking, with many not backing up the idea, explains Engelmann. But these mainly focused on positive outcomes, like winning a lottery. We examined how both positive and negative outcomes influence biased beliefs.

Choosing the most pleasant outcome

Understanding self-deception and its causes is difficult in real-world situations. The study involved a set of experiments with over 1,700 participants, conducted in a lab and online.

Participants were briefly shown various patterns, such as sets of differently oriented stripes or coloured dots, and were asked what kind of pattern they saw. Some of these patterns were linked to a negative outcome to induce anxiety, either a mild and non-dangerous electrical shock (in the lab) or a loss of money (online).

We wanted to see if people make more mistakes in recognising patterns associated with a negative outcome, thinking it was actually a harmless pattern. That would indicate wishful thinking, explains Van der Weele.

The study consistently found that participants were less likely to correctly identify patterns associated with a shock or loss.

The participants tended to see a pattern that aligned with what was more desirable, Engelmann says.

Previous research looked at wishful thinking related to positive outcomes and found mixed results, with many studies not finding an effect. Our study demonstrates very clearly thatthe negative emotionof anxiety about an outcome leads to wishful thinking.

Making people more realistic

The researchers also tested interventions designed to make people more realistic. The first involved making the patterns easier to recognise.

Reducing uncertainty did indeed turn out to reduce wishful thinking, says Van der Weele.

The second intervention was to offer higher potential earnings for correct pattern recognition. This intervention had little effect, except when participants could gather more evidence about the exact pattern they were shown.

When people had more time to collect evidence and were better rewarded for a correct answer, they became more realistic, explains Engelmann.

Finally, in the experiments where negative outcomes were replaced by positive outcomes, participants showed no wishful thinking. According to the authors this shows that reducing negative emotions can lessen overoptimism.

Wishful thinking in the real world

The authors recognise that wishful thinking can be useful because it helps us deal with bad feelings and manage uncertainty.

Engelmann: Wishful thinking is important for humans in coping with anxiety about possible future events.

For Van der Weele and Engelmann, the concern is situations in which too much optimism stops people from getting the information they need or from acting in a way that would benefit them.

People can get too hopeful when things are uncertain. We observe this happening with climate change, when financial markets fluctuate, and even in personal health situations when people avoid medical help because they think everything will be fine. We need to know more about when wishful thinking helps and when it hurts.

Author: Laura Erdtsieck Source: University of Amsterdam Contact: Laura Erdtsieck University of Amsterdam Image: The image is credited to Neuroscience News

Original Research: Open access. Anticipatory Anxiety and Wishful Thinking by Jol van der Weele et al. American Economic Review

Abstract

Anticipatory Anxiety and Wishful Thinking

Across five experiments (N = 1,714), we test whether people engage in wishful thinking to alleviate anxiety about adverse future outcomes.

Participants perform pattern recognition tasks in which some patterns may result in an electric shock or a monetary loss.

Diagnostic of wishful thinking, participants are less likely to correctly identify patterns that are associated with a shock or loss.

Wishful thinking is more pronounced under more ambiguous signals and only reduced by higher accuracy incentives when participants cognitive effort reduces ambiguity.

Wishful thinking disappears in the domain of monetary gains, indicating that negative emotions are important drivers of the phenomenon.

Go here to read the rest:
Anxiety Drives Wishful Thinking to Risky Levels - Neuroscience News

Aging Brain Cells Have Prolonged Death Process – Neuroscience News

Summary: Mature oligodendrocytes, crucial for brain function and myelin production, have an unusually prolonged death process after damage, surviving up to 45 days post-trauma, a stark contrast to the rapid demise of their younger counterparts within 24 hours.

This study illuminates a previously unknown pathway of cell longevity, suggesting a potential shift in strategies for treating aging-related damage and neurodegenerative diseases like multiple sclerosis. By utilizing innovative techniques, including a living-tissue model and a cellular death ray, the team has highlighted the need for tailored approaches in preserving myelin and supporting brain health, challenging the one-size-fits-all treatment paradigm.

Key Facts:

Source: Dartmouth College

For oligodendrocytesthe central nervous system cells critical for brain functionage may not bring wisdom, but it does come with the power to cling to life for much, much longer than scientists knew.

Thatsaccording to a new studyfeatured on the March 27 cover of theJournal of Neuroscience.

Mature oligodendrocytes took a shocking 45 days to die following a fatal trauma that killed younger cells within the expected 24 hours, Dartmouth researchers report. The findings suggest theres a new pathway for efforts to reverse or prevent the damage that aging and diseases such as multiple sclerosis cause to these important cells.

In the brain, oligodendrocytes wrap around the long, skinny connections between nerve cells known as axons, where they produce a lipid membrane called a myelin sheath that coats the axon. Axons transmit the electrical signals that nerve cells use to communicate; myelin sheathslike the plastic coating on a copper wirehelp these signals travel more efficiently.

Old age and neurodegenerative diseases like MS damage oligodendrocytes. When the cells die, their myelin production perishes with them, causing myelin sheaths to break down with nothing to replenish them. This can lead to the loss of motor function, feeling, and memory as neurons lose the ability to communicate.

Scientists have assumed that damaged oligodendrocyteslike all injured cellsinitiate a cellular self-destruct called apoptosis in which the cells kill themselves. But Dartmouth researchers discovered that mature oligodendrocytes can experience an extended life before their death that has never been seen before.

The findings pose the critical question of what in these cells changes as they mature that allows them to persist.

We found that mature cells undertake a pathway that is still controlled, but not the classical programmed cell-death pathway, saidRobert Hill, an assistant professor ofbiological sciencesand corresponding author of the paper.

We think this is showing us what happens in brains as we age and revealing a lot about how these cells die in older people, Hill said.

That unique mechanism is important for us to investigate further. We need to understand why these cells are following this pathway so we can potentially encourage or prevent it, depending on the disease context.

First author Timothy Chapman, who led the project as a PhD candidate in Hills research group, said that efforts to develop treatments for preserving myelin have focused on cultivating young oligodendrocytes and protecting mature ones. But this study suggests the cells may change significantly as they age and that a one-size-fits-all treatment might not work.

In response to the same thing, young cells go one way and old cells go another, said Chapman, who is now a postdoctoral researcher at Stanford University. If you wanted to protect the old cells, you may have to do something completely different than if you wanted to help the young cells mature. Youll likely need a dual approach.

The paper builds on a living-tissue modelthe teamreportedin the journal Nature Neurosciencein March 2023 that allows them to initiate the death of a single oligodendrocyte to observe how the cells around it react.

They reported that when an oligodendrocyte in a young brain died, the cells around it immediately replenished the lost myelin. In a brain equivalent to that of a 60-year-old, however, the surrounding cells did nothing and the myelin was lost.

That model gets us as close as we can get to the cell-death process that happens in the brain, Hill said.

Were able to model the effects of aging really well. Our ability to select a single oligodendrocyte, watch it die, and watch it regenerate or fail to regenerate allows us to understand what drives this process at the cellular level and how it can be controlled.

For the latest study, the researchers used their model to fatally damage oligodendrocyte DNA using what amounts to a cellular death raya photon-based device called 2Phatal that Hill developed. They also used the standard method for removing myelin that uses the copper-based toxin cuprizone as a comparison.

As previous studies have reported, the immature cells died quickly. But the older cells lived on, which the Dartmouth team at first interpreted as a resistance to DNA damage.

The study came into focus when the researchers examined the mature cells 45 days later using a long-term, high-resolution imaging technique developed inthe Hill lab.

Thats when we saw that it wasnt that the cells were resistant to damagethey were experiencing this extended cell death instead, Hill said.

No ones ever checked for cell death that long after DNA damage. Its the only example we can find in the literature where a cell experiences such a traumatic event and sticks around longer than a week, he said.

Because humans have oligodendrocytes for life, the cells are known to accumulate DNA damage and be more resilient than other cells, Chapman said.

Thats why we think this effect is applicable to aging. One reason these cells may persist for such a long time is because theyre used to experiencing this kind of damage naturally in aging, he said.

The study opens the first door of a vast labyrinth of more questions, Hill and Chapman say, such as whether the extended death is a good thing. It may be the equivalent of dysfunctional myelin, which is worse just sitting on an axon than if there was no myelin at all, Hill said. It isolates the cell from the surrounding tissue and essentially starves it of nutrients.

Its almost like there is garbage sitting on the axon for 45 days. Do we want to save that garbage or speed up its removal? We didnt even know that was a question until we saw this, Hill said.

If we understand the cell-death mechanism, maybe we can speed it up and get rid of that dysfunctional myelin, he said. Were always trying to save the cells and save the tissue, but you have to know if theyre worth saving.

The version of record of Oligodendrocyte Maturation Alters the Cell Death Mechanisms That Cause Demyelination was published March 27, 2024, in the Journal of Neuroscience.

Funding: This work was supported by the National Institutes of Health (R01NS122800), the Esther A. and Joseph Klingenstein Fund, the Simons Foundation, and the Department of Biological Sciences at Dartmouth.

Author: Morgan Kelly Source: Dartmouth College Contact: Morgan Kelly Dartmouth College Image: The image is credited to Neuroscience News

Original Research: Closed access. Oligodendrocyte Maturation Alters the Cell Death Mechanisms That Cause Demyelination by Robert Hill et al. Journal of Neuroscience

Abstract

Oligodendrocyte Maturation Alters the Cell Death Mechanisms That Cause Demyelination

Myelinating oligodendrocytes die in human disease and early in aging. Despite this, the mechanisms that underly oligodendrocyte death are not resolved and it is also not clear whether these mechanisms change as oligodendrocyte lineage cells are undergoing differentiation and maturation.

Here, we used a combination of intravital imaging, single-cell ablation, and cuprizone-mediated demyelination, in both female and male mice, to discover that oligodendrocyte maturation dictates the dynamics and mechanisms of cell death.

After single-cell phototoxic damage, oligodendrocyte precursor cells underwent programmed cell death within hours, differentiating oligodendrocytes died over several days, while mature oligodendrocytes took weeks to die. Importantly cells at each maturation stage all eventually died but did so with drastically different temporal dynamics and morphological features.

Consistent with this, cuprizone treatment initiated a caspase-3dependent form of rapid cell death in differentiating oligodendrocytes, while mature oligodendrocytes never activated this executioner caspase.

Instead, mature oligodendrocytes exhibited delayed cell death which was marked by DNA damage and disruption in poly-ADP-ribose subcellular localization. Thus, oligodendrocyte maturation plays a key role in determining the mechanism of death a cell undergoes in response to the same insult.

This means that oligodendrocyte maturation is important to consider when designing strategies for preventing cell death and preserving myelin while also enhancing the survival of new oligodendrocytes in demyelinating conditions.

See original here:
Aging Brain Cells Have Prolonged Death Process - Neuroscience News